Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI

飞利浦同意收购SpectraWAVE公司，借助AI推进下一代冠状动脉血管内成像和生理评估技术。

Dec 15, 2025 | 3 minute read

2025年12月15日 | 3分钟阅读

Acquisition of SpectraWAVE’s next-generation technologies including HyperVue

收购SpectraWAVE的下一代技术，包括HyperVue

TM

商标符号 (™)

Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1

具有增强血管成像功能的成像系统，用于冠状动脉内部全面、快速且支持人工智能的成像，以及X1。

TM

商标

-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1]

-FFR，一种基于冠状动脉造影的AI赋能的FFR技术，能够通过单一血管造影快速、准确地评估冠状动脉生理状况 [1]

SpectraWAVE’s technologies have the potential to significantly increase adoption of coronary intravascular imaging and physiological assessment, especially when combined with Philips’ industry-leading Azurion image-guided therapy platform, supporting better outcomes [2] for more cardiac patients

SpectraWAVE的技术有潜力显著提高冠状动脉血管内成像和生理评估的采用率，特别是当与飞利浦行业领先的Azurion影像引导治疗平台结合使用时，能够为更多心脏病患者提供更好的治疗效果[2]。

Acquisition will expand Philips’ existing intravascular imaging and physiological assessment device portfolio, featuring Eagle Eye Platinum digital IVUS and OmniWire iFR technology, to create a comprehensive offering in intravascular imaging and physiology solutions

收购将扩大飞利浦现有的血管内成像和生理评估设备组合，包括Eagle Eye Platinum数字IVUS和OmniWire iFR技术，从而在血管内成像和生理学解决方案方面提供全面的产品。

Amsterdam, the Netherlands –

荷兰阿姆斯特丹 –

Royal Philips

皇家飞利浦

(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has entered into an agreement to acquire SpectraWAVE, Inc., an innovator in Enhanced Vascular Imaging (EVI) of coronary arteries, angiography-based physiology assessments, and the use of AI in medical imaging [3]. SpectraWAVE’s intravascular imaging and physiological assessment technologies provide advanced solutions for the treatment of patients with coronary artery disease, the most frequent type of heart disease, affecting more than 300 million people worldwide [4].

(NYSE: PHG, AEX: PHIA)，作为全球健康技术的领导者，今天宣布已达成协议收购SpectraWAVE, Inc.，这是一家在冠状动脉增强血管成像（EVI）、基于血管造影的生理评估以及人工智能在医学影像中的应用方面的创新企业。SpectraWAVE的血管内成像和生理评估技术为治疗冠状动脉疾病（最常见的 心脏病类型，影响全球超过3亿人）提供了先进的解决方案。

SpectraWAVE, based in Bedford, Massachusetts, was founded in 2017 and currently employs more than 70 people..

总部位于马萨诸塞州贝德福德的SpectraWAVE公司成立于2017年，目前员工人数超过70人。

“Our global leadership in image guided therapy is driven by deep clinical collaboration combined with our latest technology insights across hardware, software and AI, to innovate interventional procedures for better and more patient impact. Our world-class portfolio integrates interventional systems and devices into one platform, Azurion, serving patients worldwide..

“我们在影像引导治疗领域的全球领先地位得益于深入的临床合作，并结合了我们在硬件、软件和人工智能方面的最新技术洞察，从而创新介入手术，为患者带来更好、更广泛的医疗效果。我们世界一流的解决方案将介入系统与设备整合到一个平台——Azurion中，为全球患者提供服务。”

“We are doubling down on image-guided therapy and expanding our portfolio in the coronary intervention segment with the addition of SpectraWAVE’s AI-powered innovations in high-definition intravascular imaging and angio-based physiological assessment, enabling us to deliver better care for more people,”.

“我们正在加倍努力于影像引导治疗，并通过增加SpectraWAVE在高清血管内成像和基于血管造影的生理评估方面的AI创新技术，扩大我们在冠状动脉介入领域的产品组合，从而能够为更多人提供更好的护理。”

said Roy Jakobs, CEO of Royal Philips.

罗伊·雅各布斯，皇家飞利浦首席执行官表示。

Percutaneous coronary interventions are minimally invasive procedures that leverage intravascular imaging and physiological assessment to treat coronary artery disease. A significant and growing body of evidence shows that the use of intravascular imaging and physiological assessment technologies significantly improves patient outcomes for percutaneous coronary interventions [5].

经皮冠状动脉介入治疗是一种微创手术，利用血管内成像和生理评估来治疗冠状动脉疾病。大量且不断增加的证据表明，使用血管内成像和生理评估技术可显著改善经皮冠状动脉介入治疗的患者预后 [5]。

With its industry-leading Azurion image-guided therapy platform, integrated with its expanding portfolio of advanced diagnostic and treatment devices, Philips is driving the adoption of advanced healthcare technology to treat a growing and increasingly complex patient population. .

通过其行业领先的Azurion影像引导治疗平台，结合其不断扩展的先进诊断和治疗设备组合，飞利浦正在推动先进医疗技术的应用，以治疗日益增长且复杂的患者群体。

“Philips shares our deep conviction that the convergence of intravascular imaging, coronary physiology and AI can fundamentally improve how every patient with coronary disease is treated. This partnership allows us to integrate and scale HyperVue and X1-FFR into the world’s leading image-guided therapy ecosystem, expanding choice for clinicians and supporting more consistent, high-quality care for the millions of patients who depend on coronary intervention each year,”.

“飞利浦与我们有着深刻的共识，即血管内成像、冠状动脉生理学和人工智能的融合可以从根本上改善每位冠心病患者的治疗方式。此次合作使我们能够将HyperVue和X1-FFR整合并扩展到全球领先的图像引导治疗生态系统中，为临床医生提供更多的选择，并支持每年依赖冠状动脉介入治疗的数百万患者获得更一致、更高质量的护理。”

said Eman Namati, PhD, CEO of SpectraWAVE.

SpectraWAVE首席执行官、博士埃曼·纳马提说道。

“With today’s announcement we continue to expand the role of minimally invasive image guided therapy procedures, which are associated with better patient outcomes and improved cost-effectiveness [6][7]. The acquisition of SpectraWAVE’s next-generation technologies for coronary intravascular imaging and physiological assessment mark a significant step in expanding our portfolio with breakthrough, AI-powered technologies that help clinicians decide, guide, treat and confirm treatment in one setting,”.

“通过今天的公告，我们继续扩大微创影像引导治疗程序的作用，这些程序与更好的患者预后和更高的成本效益相关[6][7]。收购SpectraWAVE的下一代冠状动脉血管内成像和生理评估技术，标志着我们在扩展产品组合方面迈出了重要一步，这些突破性的、由人工智能驱动的技术能够帮助临床医生在一个环境中完成决策、引导、治疗和确认治疗。”

said Bert van Meurs, Chief Business Leader Image Guided Therapy at Philips.

飞利浦影像引导治疗首席业务负责人伯特·范·米尔说。

Expanding clinician choice and integrating AI across its coronary portfolio

扩大临床医生的选择范围，并在其冠状动脉产品组合中整合人工智能

SpectraWAVE’s HyperVue Imaging System is an intravascular imaging platform that combines DeepOCT (next generation comprehensive optical coherence tomography) and NIRS (near-infrared spectroscopy) into the Enhanced Vascular Imaging (EVI) novel imaging segment to provide detailed structural and compositional images of the coronary arteries during percutaneous coronary interventions, with rapid setup, acquisition, and automated AI image analysis.

SpectraWAVE的HyperVue成像系统是一种血管内成像平台，它将DeepOCT（下一代全面光学相干断层扫描）和NIRS（近红外光谱）结合到增强血管成像（EVI）这一新型成像领域中，在经皮冠状动脉介入治疗期间提供冠状动脉的详细结构和组成图像，并具备快速设置、采集和自动化的AI图像分析功能。

Combined with Philips’ Eagle Eye Platinum digital IVUS and IntraSight technologies, HyperVue will expand clinicians’ intravascular imaging toolbox – IVUS, DeepOCT, NIRS, and wire and angio-derived physiology – all orchestrated through integrated systems to tailor guidance to each patient and lesion..

结合飞利浦的Eagle Eye Platinum数字IVUS和IntraSight技术，HyperVue将扩展临床医生的血管内成像工具箱——包括IVUS、DeepOCT、NIRS以及导丝和血管造影衍生的生理学技术——所有这些都通过集成系统进行协调，以针对每位患者和病灶提供定制化的指导。

SpectraWAVE’s X1-FFR is an angiography-derived, AI-enabled physiology solution that calculates Fractional Flow Reserve (FFR) from a single coronary angiogram, providing a non-invasive ischemia assessment and turning routine X-ray images into coronary physiology data for simplified percutaneous coronary intervention workflows.

SpectraWAVE的X1-FFR是一种基于血管造影、由人工智能驱动的生理学解决方案，它能够通过单一冠状动脉造影计算分数流储备（FFR），提供无创性缺血评估，并将常规X光图像转化为冠状动脉生理数据，从而简化经皮冠状动脉介入治疗的工作流程。

X1-FFR complements Philips OmniWire iFR technology by extending physiologic guidance to wire-free scenarios and equipping clinicians with a versatile toolkit to broaden the adoption of coronary physiology in daily practice. .

X1-FFR 通过将生理学引导扩展到无导丝场景，补充了飞利浦 OmniWire iFR 技术，并为临床医生提供了一个多功能工具包，以促进冠状动脉生理学在日常实践中的广泛应用。

Philips offers one of the most comprehensive image-guided therapy portfolios in the industry, providing solutions for visual guidance during minimally invasive procedures and image-guided therapy devices designed to enhance procedural efficiency and improve patient outcomes. At the heart of this portfolio is Azurion, Philips’ next-generation platform that brings advanced interventional tools together in a single, intuitive environment supporting a wide range of procedures across interventional cardiology, interventional radiology, neuroradiology and vascular surgery.

飞利浦提供了业内最全面的图像引导治疗产品组合之一，为微创手术中的视觉引导提供解决方案，并设计了图像引导治疗设备以提高手术效率和改善患者预后。该产品组合的核心是Azurion，飞利浦的下一代平台，将先进的介入工具集成在一个直观的环境中，支持跨介入心脏病学、介入放射学、神经放射学和血管外科的广泛手术。

Introduced in 2017, Philips Azurion is used to treat more than 7.6 million patients each year in over 80 countries..

2017年推出的飞利浦Azurion每年在80多个国家用于治疗超过760万名患者。

Financial terms of the agreement are not disclosed.

协议的财务条款未披露。

Sources

来源

[1] The SpectraWAVE HyperVue Imaging System and the Starlight Imaging Catheter is a US Class 2 device cleared by FDA through K221257 and K230691. The SpectraWAVE X1-FFR Software is a US Class 2 device cleared by FDA through K251355.

[1] SpectraWAVE HyperVue成像系统和Starlight成像导管是通过FDA的K221257和K230691批准的美国II类设备。SpectraWAVE X1-FFR软件是通过FDA的K251355批准的美国II类设备。

[2] Compared with angiography-guided Percutaneous Coronary Interventions.

与血管造影引导的经皮冠状动脉介入治疗相比。

[3] AI-derived algorithms are deployed on the device to support vessel segmentation and contouring. Analytical (non-AI) models are used for generating FFR values.

[3] 设备上部署了基于人工智能的算法，以支持血管分割和轮廓绘制。生成FFR值则使用分析性（非人工智能）模型。

[4] Stark, B., Johnson, C., & Roth, G. A. (2024). Global prevalence of coronary artery disease: An update from the Global Burden of Disease Study. Journal of the American College of Cardiology, 83(13 Suppl), 2320.

[4] 斯塔克, B., 约翰逊, C., & 罗斯, G. A. (2024). 全球冠心病患病率：来自全球疾病负担研究的更新. 美国心脏病学会杂志, 83(13 增刊), 2320.

https://doi.org/10.1016/S0735-1097(24)04310-9

https://doi.org/10.1016/S0735-1097(24)04310-9

[5] Mandurino-Mirizzi, A., Munafò, A. R., Rizzo, F., De Francesco, R., Raone, L., Germinal, F., Montalto, C., Mussardo, M., Moci, M., Vergallo, R., Rocco, V., Fischetti, D., Dionigi, F., Godino, C., Colonna, G., Oreglia, J., Burzotta, F., Crimi, G., & Porto, I. (2025). Comparison of different guidance strategies to percutaneous coronary intervention: A network meta-analysis of randomized clinical trials.

[5] 曼杜里诺-米里齐，A.，穆纳福，A. R.，里佐，F.，德·弗朗切斯科，R.，拉奥内，L.，杰尔米纳尔，F.，蒙塔尔托，C.，穆萨多，M.，莫奇，M.，维尔加洛，R.，罗科，V.，菲什蒂，D.，迪奥尼吉，F.，戈迪诺，C.，科隆纳，G.，奥雷利亚，J.，布尔佐塔，F.，克里米，G.，& 波尔托，I. （2025）。不同引导策略在经皮冠状动脉介入治疗中的比较：随机临床试验的网络荟萃分析。

International Journal of Cardiology, 422, 132936. .

国际心脏病学杂志，422卷，132936页。

https://doi.org/10.1016/j.ijcard.2024.132936

https://doi.org/10.1016/j.ijcard.2024.132936

[6] Stone, G. W., Christiansen, E. H., Ali, Z. A., Andreasen, L. N., Maehara, A., Ahmad, Y., Landmesser, U., & Holm, N. R. (2024). Intravascular imaging-guided coronary drug-eluting stent implantation: An updated network meta-analysis. The Lancet, 403(10429), 824–837.

[6] 斯通，G. W.，克里斯蒂安森，E. H.，阿里，Z. A.，安德烈森，L. N.，前原，A.，艾哈迈德，Y.，兰姆瑟，U.，霍尔姆，N. R.（2024）。血管内影像引导的冠状动脉药物洗脱支架植入：一项更新的网络荟萃分析。《柳叶刀》，403（10429），824-837。

https://doi.org/10.1016/S0140-6736(23)02454-6

https://doi.org/10.1016/S0140-6736(23)02454-6

[7] Gaster, A. L., Slothuus Skjoldborg, U., Larsen, J., Korsholm, L., von Birgelen, C., Jensen, S., Thayssen, P., Pedersen, K. E., & Haghfelt, T. H. (2003). Continued improvement of clinical outcome and cost effectiveness following intravascular ultrasound guided PCI: Insights from a prospective, randomized study.

[7] Gaster, A. L., Slothuus Skjoldborg, U., Larsen, J., Korsholm, L., von Birgelen, C., Jensen, S., Thayssen, P., Pedersen, K. E., & Haghfelt, T. H. (2003)。血管内超声引导的经皮冠状动脉介入治疗后临床结果和成本效益的持续改善：来自一项前瞻性随机研究的见解。

Heart, 89(9), 1043–1049. .

心脏，89（9），1043-1049。

https://doi.org/10.1136/heart.89.9.1043

https://doi.org/10.1136/heart.89.9.1043

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home..

皇家飞利浦（纽约证券交易所代码：PHG，阿姆斯特丹泛欧交易所代码：PHIA）是一家领先的健康技术公司，致力于通过有意义的创新改善人们的健康和福祉。飞利浦以患者和用户为中心的创新利用先进技术，并结合深入的临床和消费者洞察，为消费者提供个人健康解决方案，同时为医疗机构及其患者在医院和家庭环境中提供专业的健康解决方案。

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,000 employees with sales and services in more than 100 countries.

总部位于荷兰的飞利浦是诊断影像、超声、影像引导治疗、监测和企业信息学以及个人健康领域的领导者。2024年，飞利浦实现了180亿欧元的销售额，在全球100多个国家拥有约67,000名员工，负责销售和服务。

News about Philips can be found at .

有关飞利浦的新闻可以在找到。

www.philips.com/newscenter

www.philips.com/newscenter

.

。

This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments.

本发布包含某些关于飞利浦财务状况、运营结果及其业务的前瞻性陈述，以及飞利浦针对这些事项的某些计划和目标。前瞻性陈述的例子包括有关战略、销售增长预测、未来EBITA、飞利浦核心业务未来发展以及收购和剥离完成情况的声明。

By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements..

这些陈述本质上涉及风险和不确定性，因为它们与未来事件和情况相关，而且有许多因素可能导致实际结果和发展与这些陈述所表达或暗示的内容存在重大差异。

Media contacts

媒体联系人

Get our latest news by e-mail

通过电子邮件获取我们的最新消息

Share this page

分享此页面